Citation Impact
Citing Papers
Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2
2011 Standout
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Rofecoxib
2001
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
2020 Standout
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
2007
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers
2007
Does nicotinic acid (niacin) lower blood pressure?
2008
Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
2008
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
2000 Standout
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
2008
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
2006
Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides
1988 Standout
Gastrointestinal defense mechanisms
2011
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
2010
Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
2007
Biology of Incretins: GLP-1 and GIP
2007 Standout
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
2006 Standout
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
2010
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
2010 Standout
Type 1 diabetes
2013 Standout
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
2010
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
The Physiology of Glucagon-like Peptide 1
2007 Standout
Type 2 diabetes mellitus
2015 Standout
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
2010
C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
2009
Glycaemic control in type 2 diabetes: Targets and new therapies
2009
Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: A Review of Emerging Therapies for Type 2 Diabetes
2006
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
Fluorine in medicinal chemistry
2007 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery
2013 Standout
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
The Many Roles for Fluorine in Medicinal Chemistry
2008 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
2010
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
2006
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Green synthesis of zinc oxide nanoparticles using Hibiscus subdariffa leaf extract: effect of temperature on synthesis, anti-bacterial activity and anti-diabetic activity
2014 Standout
Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers
2000
Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules
2006 Standout
Mechanisms of Diabetic Complications
2013 Standout
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
2007
Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes
2006
The Metabolic Syndrome
2008 Standout
An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
2016
Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of [alpha]2B adrenoceptors.
2000 StandoutNobel
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study
2020 Standout
Fluorination in Medicinal Chemistry: Methods, Strategies, and Recent Developments
2008 Standout
Works of D Hilliard being referenced
Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist
2007
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
2005
Demonstration of specific COX-2 inhibition by MK-966 in humans with supratherapeutic doses
1999